Member Info for desamax

Sorry about that as I meant to post it on SAR. As it was related to Sar.

https://www.google.com/amp/s/www.standard.co.uk/news/uk/deborah-james-the-big-c-radio-5-live-bbc-presenter-bowel-cancer-a4335706.html%3Famp

https://www.google.com/amp/s/www.standard.co.uk/news/uk/deborah-james-the-big-c-radio-5-live-bbc-presenter-bowel-cancer-a4335706.html%3Famp

His namesake once said “they think it’s all over”........

This time, far too many false dawns, “it bloody works” multiple talks ongoing, then up pops a brand new firm to try to raise 5mill. This should e a tv series.

Are a bit underwhelming,

15% rise near 15%?spread. No one is up even on today’s going’s on. Please please let my pessimism be wrong. As much as my optimism has been.

They had to Change tactics

why is today so different, Seems every time a placing is announced P+D with more PIs locked in, id wait till nearer 1p before jumping in. If this is going to have the legs some are predicting. Don't get me wrong id love my 2.5p history could repeat itself .
GLA, LTHs

Its what amount you have put in here that counts, most of us are down 99.99 %

If a buyout is on the way, what SP would the enlightened expect us to receive around 5p or more or less?

???

Most traders are on the Xmas break, just the skeletons are in today and till the new year. Someone will be having fun and games with this one. Would be good if the rise is continued into 2020 to help LTHs who were caught out by the last speeding ticket. I was in here when they 10-1 now only have a few up for none. GLA

What’s happening over the pond?
Talk earlier of a big rise has not materialised. Until Serra gets back on track, it will be a waiting game.

Any news from his comments this evening?

Sierra is also developing a portfolio of DNA Damage Response (DDR) assets, consisting of SRA737 and SRA141, and is conducting a campaign intended to seek non-dilutive strategic options to support their further advancement. SRA737 is a potent, highly selective, orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1), a key regulator of cell cycle progression and the DDR, and has demonstrated preliminary clinical efficacy. SRA141 is a potent, selective, orally bioavailable small molecule inhibitor of Cell division cycle 7 kinase (Cdc7) with a potential novel mechanism of cytotoxicity, and has successfully completed the IND process with the FDA enabling the commencement of clinical trials.

Sierra Oncology retains the global commercialization rights to momelotinib, SRA737 and SRA141. For more information, please visit www.sierraoncology.com.

https://finance.yahoo.com/news/sierra-oncology-reports-third-quarter-210100539.html

Breakfast Buffet
Sareum Holdings* (SAR.L) 0.36p £10.75m

Sareum’s CEO, Dr Tim Mitchell, presented data yesterday demonstrating how SDC-1802 (formerly known as SAR-20351), a novel selective TYK2/JAK1 inhibitor discovered by Sareum, significantly reduces tumour growth in disease models of cancers of the pancreas, colon, skin and kidney, plus B-cell lymphoma. The studies showed that SDC-1802 induces this anti-cancer activity through a novel immunotherapeutic mechanism of action that stimulates the local immune system to attack cancer cells.
“There was a good level of interest directed at novel immunotherapy mechanisms such as TYK2/JAK1 inhibition and we look forward to further discussions with interested parties.”

Redde (REDD.L) 114.09p £350m

https://twitter.com/hybridanllp/status/1189446572519710720?s=21

UT !